Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.

Here we report an activity-dependent stabilization of the MAP kinase (MAPK ... Figure 4: Continuous upstream activation of MEK during the post-stimulus stabilized state. Because MEK/MAPK signaling ...

In contrast to currently available MEK-only inhibitors, avutometinib blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. This unique mechanism allows avutometinib to block ...

Assessment of transfer entropy is useful for network analysis of cell signaling network providing information on the network topology and action points of genetic mutations and drug effect, thus will ...

I study and characterize the response to KRAS G12C, SOS1 and SHP2 inhibitors alone or in combination with receptor tyrosine kinase (RTK) or MEK inhibitors in different tumor types to determine the ...